Additionally, methionine (MET) treatment, which raises S-adenosyl methionine (SAM) levels, a cofactor for DNMT1, further enhances promoter methylation and gene silencing in schizophrenia-related pathways (Grayson et al., 2009). The gene discussed is DNMT1; the disease is schizophrenia.